Pemirolast

CAT: 0804-HY-137863Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-137863Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Pemirolast is an orally active antiallergic agent. Pemirolast attenuates Paclitaxel (HY-B0015) hypersensitivity reactions. Pemirolast can be used for bronchial asthma and conjunctivitis research[1]-[5].
CAS Number
[69372-19-6]
UNSPSC
12352005
Target
Histamine Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/pemirolast.html
Solubility
DMF : < 1 mg/mL (ultrasonic)|DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1C(C2=NNN=N2)=CN=C3N1C=CC=C3C
Molecular Formula
C10H8N6O
Molecular Weight
228.21
References & Citations
[1]Kawashima T, et al. Inhibitory effect of pemirolast, a novel antiallergic drug, on leukotriene C4 and granule protein release from human eosinophils. Int Arch Allergy Immunol. 1994;103 (4) :405-9. |[2]Yanni JM, et al. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immunol. 1997 Dec;79 (6) :541-5. |[3]Fujimiya H, et al. Effect of a novel antiallergic drug, pemirolast, on activation of rat peritoneal mast cells: inhibition of exocytotic response and membrane phospholipid turnover. Int Arch Allergy Appl Immunol. 1991;96 (1) :62-7.|[4]Itoh Y, et al. Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats. Neuropharmacology. 2004 May;46 (6) :888-94.|[5]Tatsushima Y, et al. Pemirolast reduces cisplatin-induced kaolin intake in rats. Eur J Pharmacol. 2011 Jul 1;661 (1-3) :57-62.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched

Related Products

CatalogName

Popular Products